tert-butyl 4-(4-formyl-3-methoxyphenyl)-1,4-diazepane-1-carboxylate | 1374858-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl 4-(4-formyl-3-methoxyphenyl)-1,4-diazepane-1-carboxylate
• CAS: 1374858-57-7
• 化学式: C₁₈H₂₆N₂O₄
• 分子量: 334.415
• InChiKey: CTYRVTCFVUKJED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.95
• 重原子数：
  24.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  59.08
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-formyl-3-methoxyphenyl)-1,4-diazepane-1-carboxylate 在 盐酸 、 sulfur 作用下， 以 甲醇 、 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 3.0h， 生成 5-cyclohexyl-2-[4-(1,4-diazepan-1-yl)-2-methoxyphenyl]-7-methyl-3H-imidazo[4,5-d]pyridazin-4-one
  参考文献：
  名称：

  Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model

  摘要：

  The synthesis and structure-activity relationship studies of a series of compounds from imidazopyridazinone scaffold as PDE7 inhibitors are disclosed. Potent analogs such as compounds 7 (31 nM), 8 (27 nM), and 9 (12 nM) were identified. The PDE selectivity and pharmacokinetic profile of compounds 7, 8 and 9 are also disclosed. The adequate CNS penetration of compound 7 in mice allowed it to be tested in the MPTP induced PD model and haloperidol induced catalepsy model to probe the differential pharmacology of PDE7 in the striatal pathway. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.077
• 作为产物：
  描述：

  4-氟-2-甲氧基苯甲醛 、 1,4-二氮杂环庚烷-1-甲酸叔丁酯 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 以70%的产率得到tert-butyl 4-(4-formyl-3-methoxyphenyl)-1,4-diazepane-1-carboxylate
  参考文献：
  名称：

  Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model

  摘要：

  The synthesis and structure-activity relationship studies of a series of compounds from imidazopyridazinone scaffold as PDE7 inhibitors are disclosed. Potent analogs such as compounds 7 (31 nM), 8 (27 nM), and 9 (12 nM) were identified. The PDE selectivity and pharmacokinetic profile of compounds 7, 8 and 9 are also disclosed. The adequate CNS penetration of compound 7 in mice allowed it to be tested in the MPTP induced PD model and haloperidol induced catalepsy model to probe the differential pharmacology of PDE7 in the striatal pathway. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.077

文献信息

• Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation
  作者：Abhisek Banerjee、Pravin S. Yadav、Malini Bajpai、Ramachandra Rao Sangana、Srinivas Gullapalli、Girish S. Gudi、Laxmikant A. Gharat

  DOI：10.1016/j.bmcl.2012.03.025

  日期：2012.5

  The synthesis and structure-activity relationship studies of isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors are discussed. The pharmacokinetic profile of 10 and 21 with adequate CNS penetration, required for in vivo Parkinson's disease models, are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.